Cangene wins US OK for VariZIG to reduce chickenpox severity; shares jump
This article was originally published in Scrip
Executive Summary
Shares of Winnipeg, Manitoba-based Cangene jumped more than 17% on 21 December after the Canadian biotech gained the US FDA's OK to market VariZIG (varicella zoster immune globulin/VZIG) as an intramuscular post-exposure prophylaxis to reduce the severity of chickenpox in people at high risk of developing the virus, also known as varicella zoster (VZV).